Clinical Trial Update: Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial evaluated paclitaxel/carboplatin/bevacizumab with PF-3512676 versus paclitaxel/carboplatin/bevacizumab alone in advanced nonsquamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• PF-3512676

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED